EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.
Issue link: https://digital.eyeworld.org/i/307230
it will improve on its own, but it
may improve faster with treatment.
LASIK satisfaction overall is ex-
tremely high, but there are a few
vocal patients who are very un-
happy."
Dr. Pflugfelder said those pa-
tients may be experiencing some-
thing beyond dry eye, a type of
neuralgia.
"The problem with post-LASIK
dry eye is a lot of people who are di-
agnosed as having dry eye after
LASIK really don't have dry eye. If
they have irritation symptoms or
pain, they may actually have a type
of neuralgia due to the way that the
nerves seal in the cornea. They be-
come hypersensitized and it can
drive them crazy," he said.
Identifying the patients and
treating them before operating can
make a good procedure even better,
Dr. Pflugfelder said. The same is true
with multifocal IOL patients, he
added.
"On a weekly basis, I see people
with pretty bad dry eye after LASIK
who probably should never have
had the procedure to begin with,"
he said. "With multifocal IOL pa-
tients, a big problem is if they do
have dry eye or an unstable tear film
and you implant a multifocal IOL, it
will divide light rays for distance
and near. The light that now comes
in the eye and hits the multifocal
IOL no longer gives 100% of the
light rays for distance or near. Con-
trast sensitivity goes down a little
crucial," Dr. Pflugfelder said. "The
deeper the laser ablation, the more
chance patients are going to have
dry eye, especially with LASIK be-
cause you're already cutting the flap
and ablating deeper."
Hyperopic LASIK increases the
risk.
"I've seen some really miserable
patients, especially hyperopic LASIK
patients, because it's a bigger flap
and bigger treatment zone," Dr.
Pflugfelder said. "I think those pa-
tients are probably better off having
refractive lens exchange because
there's minimal risk of dry eye, and
the quality of their vision would be
a
lot better."
Dr. Trattler agreed about the size
of the flaps created during LASIK.
"We believe that thinner flaps re-
duce the risk of developing dry eye
afterward. Also, with a deeper flap,
we sever more corneal nerves," he
said. "A deeper, wider flap can make
bit. In someone
with a normal tear
film, that's OK, but
if the patient has
an abnormal tear
film, it can de-
crease contrast sen-
sitivity
and scatter
light. It can drive
some people with a
multifocal IOL
crazy."
Avoid dry eye in
surgery
Creating
smaller
flaps during LASIK
can help mitigate
some of the follow-
up dry eye compli-
cations, both
surgeons said.
"Smaller flaps are probably bet-
ter because they don't cut as many
nerves. The depth of the ablation is
Using DEWS
Dr. Pflugfelder said he uses the Dry
Eye Workshop (DEWS) system to
evaluate a framework for treatment.
DEWS was published in the April
2007 issue of The Ocular Surface as a
follow up to the Delphi panel spon-
sored by the National Eye Institute
and ophthalmic industry. Dr.
Pflugfelder was the chairman of the
management and therapy subcom-
mittee.
DEWS, which expanded on the
Delphi criteria, identified dry eye as
"a multifactorial disease of the tears
and ocular surface that results in
symptoms of discomfort, visual dis-
turbance, and tear film instability
with potential damage to the ocular
surface. It is accompanied by in-
creased osmolarity of the tear film
and inflammation of the ocular sur-
face."
It classified the etiology of the
disease into two categories: aqueous
tear deficient and evaporative.
"With level 2 or worse, steroids
should probably be used for treat-
ment, at least short term," Dr.
Pflugfelder said. "No one in level 4
should have LASIK. These people
might not even be good candidates
for IOLs."
Although post-op dry eye can be
nerve-wracking for patients, Dr.
Pflugfelder said it will resolve with
time.
"Tear function tends to improve
over the first 6 months after LASIK,"
he said. "The natural history is that
EW FEATURE
43
February 2011
April 2011 OCULAR SURFACE
INTRODUCING
(9L]VS\[PVUPU[OL;YLH[TLU[
VM(J\[L,`LSPK*VUKP[PVUZ
Ocudox
™
(Doxycycline Hyclate 50 mg) is indicated to reduce the development of drug-resistant bacteria and should be used only to treat or prevent infections that are proven
or strongly suspected to be caused by bacteria. Ocudox
™
is contraindicated in persons who have shown hypersensitivity to doxycycline or any of the other tetracyclines.
Doxycycline can cause fetal harm when administered to a pregnant woman. The use of drugs of the tetracycline class during tooth development (last half of pregnancy,
infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth. Tetracycline drugs should not be used during tooth development or in pregnant
or nursing mothers. Photosensitivity can occur with any tetracycline-class drugs. For full prescribing information, visit www.ocudox.com. NDC 54799-535-60
© 2011 OCuSOFT, Inc., Richmond, TX 77406
1
'DWDRQ¿OH2&X62)7,QF
-VYTVYLPUMVYTH[PVUJHSS VY]PZP[^^^VJ\KV_JVT
sÛ.BTCNW
™
Û
+V_`J`JSPUL/`JSH[LTN*HWZ\SLZ<:7
sÛÛ."T2.%3
®
Û+HCÛ2BQTA
™
Û/+42Û,_[YH:[YLUN[O,`LSPK*SLHUZLY
*VU]LUPLU[¸SLH]LVU¹MVYT\SHVMMLYZHU[PIHJ[LYPHSWYVWLY[PLZ
sÛ3D@QRÛ F@HM
®
ÛHK]HUJLK+HONRNLDÛ2OQ@XÛ